The global contract research organization (CRO) service market is set to reach USD 186.317 billion in 2031, growing at a CAGR of 7.22% from a valuation of USD 131.459 billion in 2026.
Contract Research Organizations (CRO) Services Market Highlights:
The market for global contract research organisation (CRO) services is critical to providing outsourced research and development (R&D) solutions for the pharmaceutical, biopharmaceutical, and medical device industries. CRO's specialised service offerings, such as preclinical studies, clinical trial activities, laboratory testing, and regulatory consulting, allow the Pharmaceutical, Biopharmaceutical, and Medical Device industries to develop new therapies faster and at a lower cost.
The main drivers of growth in the CRO services market are the increasing demand for new and innovative therapies, the biopharmaceutical industry's ongoing trend of outsourcing, and the need to create efficiencies in clinical development. By developing products to meet the diverse needs and capabilities of successful healthcare companies worldwide, CROs have continued to foster and drive innovation while reducing operational burdens on these companies.
Contract Research Organizations (CRO) Services Market Trends:
The Contract Research Organisation (CRO) Services market includes professional services provided by research organisations that focus on contract clinical trials and bioavailability and/or bioequivalence studies on behalf of sponsors involved in developing new drugs. In India, the Government of India’s Ministry of Health & Family Welfare amended the New Drugs & Clinical Trial Regulations via G.S.R. 581 (E) dated 19 September 2024, with an effective date of 1 April 2025.
It defined CROs and began a regulatory system for dictating how CROs will be registered and operated. Specifically, as per these amended regulations, only CROs that have received registration from the Central Licensing Authority (CLA) are permitted to conduct clinical trials or other studies involving human subjects.
To help CROs comply with this new rule, the Central Drugs Standard Control Organisation, a part of the Government of India, has employed an online registry through the SUGAM portal. Effective 1 April 2025, it will be required that all CROs process their applications for CRO Registration on the SUGAM portal and submit the required documentation, as well as the appropriate fee, before beginning regulated research activities.
These regulatory changes create a consistent baseline for CRO Services in India. This will allow CROs nationwide to maintain consistency in meeting standardised compliance, oversight, and ethical best practices in their role as part of the National Clinical Research Framework.
Growth of the global drug discovery outsourcing market from USD 3.8 billion in 2022 to an expected USD 6.2 billion by 2031 reflects rising demand for discovery chemical services in pharmaceutical R&D. Surging demand for discovery chemical services feeds directly into the Contract Research Organisation Services market because drug developers are increasingly outsourcing early-stage research work to specialised providers.
As pharmaceutical companies focus internal resources on later-stage development, they rely on CROs for chemistry, biological screening, and lead optimisation expertise, expanding service volumes and revenues across the CRO ecosystem.
Global Contract Research Organizations (CRO) Services Market Drivers:
Global Contract Research Organizations (CRO) Services Market Segmentation Analysis
By Molecule Type: Cell Gene Therapy
By molecule type, the Contract Research Organizations (CRO) Services Market is segmented into vaccines, cell gene therapy, and others. The cell gene therapy segment is expected to witness strong demand driven by the rise in chronic and rare genetic diseases, including cancer, cardiovascular disease, genetic disorders, and autoimmune diseases.
Cell and gene therapies involve modification of patient cells and require extensive clinical trial support, regulatory compliance, data management, and patient recruitment. As a result, biopharmaceutical companies increasingly partner with CROs to support these complex development programs.
By End-User: Pharmaceutical and Biopharmaceutical Companies
Pharmaceutical and biopharmaceutical companies represent a dominant end-user segment, driven by significant investment in biologics and therapies targeting life-threatening and rare diseases. Growth in the global clinical trial pipeline and increasing regulatory complexity continue to reinforce reliance on CRO services.
Global Contract Research Organizations Market Geographical Outlook:
North America: United States
The pharmaceutical sector in the United States is experiencing a shift toward patient-centric drug development, supported by evolving regulatory guidance from the Food and Drug Administration (FDA). Continued approvals of novel drugs and increased R&D investment are driving demand for specialized CRO expertise.
Strategic collaborations, acquisitions, and government funding through agencies such as the National Institutes of Health further shape the CRO market landscape. However, ongoing tariff pressures and regulatory complexity may introduce operational challenges for CRO service providers.
Global Contract Research Organizations Market Latest Developments:
The Global Contract Research Organizations Market is analyzed into the following segments: